Intratumoral administration of astatine-211-labeled gold nanoparticle for alpha therapy

por Kato, Hiroki, Huang, Xuhao, Kadonaga, Yuichiro, Katayama, Daisuke, Ooe, Kazuhiro, Shimoyama, Atsushi, Kabayama, Kazuya, Toyoshima, Atsushi, Shinohara, Atsushi, Hatazawa, Jun, Fukase, Koichi
Publicado 2021

Astatine-211-Labeled Gold Nanoparticles for Targeted Alpha-Particle Therapy via Intravenous Injection

por Huang, Xuhao, Kaneda-Nakashima, Kazuko, Kadonaga, Yuichiro, Kabayama, Kazuya, Shimoyama, Atsushi, Ooe, Kazuhiro, Kato, Hiroki, Toyoshima, Atsushi, Shinohara, Atsushi, Haba, Hiromitsu, Wang, Yang, Fukase, Koichi
Publicado 2022

Targeted α-therapy using astatine ((211)At)-labeled PSMA1, 5, and 6: a preclinical evaluation as a novel compound

por Watabe, Tadashi, Kaneda-Nakashima, Kazuko, Shirakami, Yoshifumi, Kadonaga, Yuichiro, Ooe, Kazuhiro, Wang, Yang, Haba, Hiromitsu, Toyoshima, Atsushi, Cardinale, Jens, Giesel, Frederik L., Tomiyama, Noriyuki, Fukase, Koichi
Publicado 2022

Evaluation of Astatine-211-Labeled Fibroblast Activation Protein Inhibitor (FAPI): Comparison of Different Linkers with Polyethylene Glycol and Piperazine

por Aso, Ayaka, Nabetani, Hinako, Matsuura, Yoshifumi, Kadonaga, Yuichiro, Shirakami, Yoshifumi, Watabe, Tadashi, Yoshiya, Taku, Mochizuki, Masayoshi, Ooe, Kazuhiro, Kawakami, Atsuko, Jinno, Naoya, Toyoshima, Atsushi, Haba, Hiromitsu, Wang, Yang, Cardinale, Jens, Giesel, Frederik Lars, Shimoyama, Atsushi, Kaneda-Nakashima, Kazuko, Fukase, Koichi
Publicado 2023